ARVN
Arvinas, Inc.
There isn't enough reported data to score ARVN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ARVN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ARVN's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ARVN PE Valuation
ARVN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ARVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARVN's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ARVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.10 | +$0.71 |
| Q2 2026 | $0.24 | +$1.25 |
| Q1 2026 | -$3.18 | -$2.52 |
| Q4 2025 | -$1.14 | +$1.63 |
| Q3 2025 | -$0.81 | +$3.86 |
| Q2 2025 | -$1.01 | +$4.16 |
| Q1 2025 | -$0.66 | +$5.27 |
| Q4 2024 | -$2.77 | +$3.73 |
ARVN is still losing money, but far less than before: $0.10 per share over the past year, against $6.50 at its worst in late 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ARVN on earnings quality, reporting a profit while its opponent remains loss making.
ARVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $500K | -99% |
| Q2 2026 | $249.7M | +1015% |
| Q1 2026 | $15.6M | -92% |
| Q4 2025 | $9.5M | -84% |
| Q3 2025 | $41.9M | -59% |
| Q2 2025 | $22.4M | -71% |
| Q1 2025 | $188.8M | +646% |
| Q3 2024 | $102.4M | +196% |
ARVN's revenue is shrinking: $500,000 last quarter, down 99% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11820% | -11716 points |
| Q2 2026 | 66% | +385 points |
| Q1 2026 | -409% | -447 points |
| Q4 2025 | -785% | -687 points |
| Q3 2025 | -105% | -46 points |
| Q2 2025 | -319% | -256 points |
| Q1 2025 | 38% | +367 points |
| Q4 2024 | -98% | N/A |
ARVN's operating margin was −11820% last quarter, down 11715 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ARVN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ARVN on profitability, with a higher operating margin.
ARVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.2M | +$49M |
| Q2 2026 | -$48.5M | +$48.1M |
| Q1 2026 | -$70.5M | +$18.8M |
| Q4 2025 | -$30.6M | +$53.8M |
| Q3 2025 | -$59.2M | +$69.5M |
| Q2 2025 | -$96.6M | -295% |
| Q1 2025 | -$89.3M | +$8.3M |
| Q4 2024 | -$84.4M | -$1.2M |
ARVN has burned cash in almost every quarter: −$160M over the past year, against −$330M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ARVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -300K shares |
| 1 year | -11% | -7.8M shares |
| 3 years | +21% | +11.3M shares |
| 5 years | +31% | +15.6M shares |
| Available history | +75% | +28.1M shares |
ARVN has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $74.1M |
| Q4 2023 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ARVN Net Leverage
ARVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ARVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 18.1 | Oversold |
ARVN's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ARVN PE vs Healthcare Sector
| Metric | ARVN | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 27% above |
ARVN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over ARVN on valuation relative to its sector.
ARVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.26 | 5.4% below |
| 20 week MA | $8.06 | 15% below |
| 50 week MA | $9.82 | 30% below |
| 100 week MA | $10.2 | 33% below |
| 200 week MA | $19.7 | 65% below |
ARVN is in a downtrend: it's below all five of its weekly moving averages, and 65% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ARVN on trend strength, trading above more of its moving averages.
ARVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.8 | $82.2 | +97% |
| 2021 | $82.2 | $81.3 | -1.2% |
| 2022 | $81.3 | $32.7 | -60% |
| 2023 | $32.7 | $41.2 | +26% |
| 2024 | $41.2 | $19.0 | -54% |
| 2025 | $19.0 | $12.2 | -36% |
| 2026 YTD | $12.2 | $6.87 | -44% |
ARVN has finished lower in four of the last six years. It's down 44% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ARVN on returns for 2026, with the stronger performance.